Will Pradaxa catch up with launching it as reversal agent?
Novel oral anticoagulants(NOAC) have started to be ranked in a year after they were applied for the National Health Insurance as the primary treatment for stroke prevention in treating stroke and embolism for atrial fibrillation(SPAF) patients.
While ‘Xarelto(generic name: rivaroxaban)’ was aggr...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
